{"disease":{"id":"generalized-lipodystrophy","name":"generalized lipodystrophy"},"drugs":{"marketed":[{"drug_id":"metreleptin","indication_name":"Acquired generalized lipodystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myalept","generic_name":"METRELEPTIN","company_name":"Amylin Pharms Llc","drug_phase":"marketed","molecular_target":"Leptin receptor","drug_class":"Leptin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Myalept works by mimicking the action of leptin, a hormone that regulates fat distribution and metabolism."},{"drug_id":"metreleptin","indication_name":"Congenital generalized lipodystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myalept","generic_name":"METRELEPTIN","company_name":"Amylin Pharms Llc","drug_phase":"marketed","molecular_target":"Leptin receptor","drug_class":"Leptin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Myalept works by mimicking the action of leptin, a hormone that regulates fat distribution and metabolism."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07220785","title":"Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04159415","title":"Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT06502990","title":"Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Amryt Pharma","has_results":false},{"nct_id":"NCT04026178","title":"Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Aegerion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06548100","title":"A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04710056","title":"Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}